Prostate Cancer - Results from #2920

Identifying Men Who Can Remain on Active Surveillance Despite Biopsy Reclassification to Grade Group 2 Prostate Cancer. April 14, 2023

A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients. April 13, 2023

External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. April 13, 2023

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. April 13, 2023

Low-Value Prostate-Specific Antigen Screening in Older Males. April 13, 2023

Unknown Causes of Death in Cancer Patients. April 13, 2023

Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation. April 13, 2023

Distinct mesenchymal cell states mediate prostate cancer progression. April 13, 2023

BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade. April 13, 2023

ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer. April 13, 2023

MYC reshapes CTCF-mediated chromatin architecture in prostate cancer. April 13, 2023

Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. April 12, 2023

Disparities in access to robotic technology and perioperative outcomes among patients treated with radical prostatectomy. April 12, 2023

Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial [version 2; peer review: 2 approved]. April 12, 2023

A matched-pair analysis comparing systematic prostate biopsy by conventional transrectal ultrasound-guidance versus software-based predefined 3D-guidance. April 12, 2023

External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy. April 12, 2023

Diagnostic and cost-effectiveness of axial skeleton MRI in staging high-risk prostate cancer. April 12, 2023

Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer. April 11, 2023

Serum testosterone and prostate cancer in men with germline BRCA1/2 pathogenic variants. April 11, 2023

A modeling study to estimate prostate cancer-specific mortality on active surveillance for men with favorable intermediate-risk prostate cancer: Results from the SEARCH cohort. April 11, 2023

Page 147 of 1439